School of Pharmacy
The University of Mississippi

Dr. Jason Paris

Posted on: July 18th, 2017 by
Research Associate Professor of Pharmacology and Research Associate Professor in RIPS
Faser 315
662-915-3096
 

Education:

  • Ph.D. The University at Albany-SUNY, Albany, NY
  • B.S. Marywood University, Scranton, PA

Appointment(s):

  • Research Associate Professor
  • Research Associate Professor in the Research Institute of Pharmaceutical Sciences

Research Interests:

Dr. Paris’ research aims to: 

(1) Understand the affective, cognitive, sensory, and reward-related pathology associated with addiction and co-morbid neurodegenerative disease states (including neuroAIDS and accelerated aging)

(2) Identify natural and pharmacological therapeutics that can ameliorate sequelae associated with addiction and neurodegeneration

His lab uses an array of behavioral, cellular, and molecular techniques to model addiction and neurodegenerative disease so that novel strategies for therapeutic intervention can be assessed. Primarily, his lab is engaged in work to understand and ameliorate the neuroendocrine factors that may be dysregulated by drugs of abuse (injection psychostimulants and opioids as well as prescription medications) and associated disease states, including neuroAIDS.  

Career Highlights:

Dr. Paris received his B.S. from Marywood University, completing an Honors Thesis on the role of circulating sex steroids and cognition in people. He attained his Ph.D. in Behavioral Neuroscience at The University at Albany-SUNY where he examined the role of neurosteroids on affect, cognition, and natural- and drug-of-abuse-related reward. In his postdoctoral work, Dr. Paris applied his prior training to examine the neuroendocrine mechanisms that may be involved in the behavioral and cellular pathology associated with drugs of abuse and neuroAIDS.  

Publications:

1) Paris JJ, Franco C, Sodano R, Freidenberg B, Gordis E, Anderson DA, Forsyth JP, Wulfert E, Frye CA. (2010). Sex differences in salivary cortisol in response to acute stressors among healthy participants, in recreational or pathological gamblers, and in those with posttraumatic stress disorder. Horm Behav. 57:35-45. doi: 10.1016/j.yhbeh.2009.06.003
2) Paris JJ, Walf AA, Frye CA. (2011). II. Cognitive performance of middle-aged female rats is influenced by capacity to metabolize progesterone in the prefrontal cortex and hippocampus. Brain Res. 1379:149-63. doi: 10.1016/j.brainres.2010.10.099
3) Paris JJ, Eans SO, Mizrachi E, Reilley KJ, Ganno ML, McLaughlin JP. (2013). Central administration of angiotensin IV rapidly enhances novel object recognition among mice. Neuropharmacology. 70C:247-253. doi: 10.1016/j.neuropharm.2013.01.025
4) Paris JJ, Singh HD, Ganno ML, Jackson P, McLaughlin JP. (2014). Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 accessory protein, Tat. Psychopharmacology. 231:2349-60. doi: 10.1007/s00213-013-3385-1
5) Paris JJ, Fenwick J, McLaughlin JP. (2014). Progesterone protects normative anxiety-like responding among female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS. Horm Behav. 65:445-53. doi: 10.1016/j.yhbeh.2014.04.001
6) Paris JJ, Fenwick J, McLaughlin JP. (2014). Estrous cycle and HIV-1 Tat protein influence cocaine-conditioned place preference and induced locomotion of female mice. Curr HIV Res. 12:388-96. doi: 10.2174/1570162X13666150121105221
7) Paris JJ, Carey AN, Shay CF, Gomes SM, He JJ, McLaughlin JP. (2014). Effects of conditional central expression of HIV-1 Tat protein to potentiate cocaine mediated psychostimulation and reward among male mice. Neuropsychopharmacology. 39:380-8. doi: 10.1038/npp.2013.201
8) Paris JJ, Singh HD, Carey AN, McLaughlin JP. (2015). Exposure to HIV-1 Tat in brain impairs sensorimotor gating and activates microglia in limbic and extralimbic brain regions of male mice. Behav Brain Res. 291:209-18. doi: 10.1016/j.bbr.2015.05.021
9) Paris JJ, Zou S, Hahn YK, Knapp PE, Hauser KF. (2016). 5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat. Brain Behav Immun. 55:202-14. doi: 10.1016/j.bbi.2013.01.007
10) Schier CJ, Marks WD, Paris JJ, Barbour AJ, McLane VD, Maragos WF, McQuiston AR, Knapp PE, Hauser KF. (2017). Selective vulnerability of striatal D2 versus D1 dopamine receptor-expressing medium spiny neurons in HIV-1 Tat transgenic male mice. J Neurosci. 37:5758-69. doi: 10.1523/JNEUROSCI.0622-17.2017.
 

Dr. Paris’ full bibliography